Comparison of the outcomes of patients with primary central nervous system lymphoma between the neurosurgery and hematology/oncology departments based on the relative dose intensity of methotrexate

Primary central nervous system lymphoma (PCNSL) is an extranodal type of lymphoma, which treated with methotrexate (MTX)‑based induction therapy. Although PCNSL a hematological malignancy, patients may be at neurosurgery or hematology/oncology departments; however, the outcomes treatment have not been compared between these two departments. The present study 26 newly diagnosed that were Department Neurological Surgery Hematology/Oncology (Wakayama Medical University Hospital, Wakayama, Japan) January 2011 and December 2021. relative dose intensity (RDI) MTX assessed as indicators chemotherapy. median RDI was 67 93% in groups, respectively (P<0.001). proportion achieved complete response after high‑dose MTX‑based therapy significantly higher group than (P=0.038). estimated 2‑year overall survival 72 100% (P=0.046). As difference observed pediatrics hematology departments for adolescents acute lymphoblastic leukemia, differ